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Abstract
Introduction: As many as 3% of computed tomography (CT) scans detect pancreatic cysts. Because
pancreatic cysts are incidental, ubiquitous and poorly understood, follow-up is often not performed.
Pancreatic cysts may have a significant malignant potential and their identification represents a ‘window
of opportunity’ for the early detection of pancreatic cancer. The purpose of this study was to implement
an automated Natural Language Processing (NLP)-based pancreatic cyst identification system.
Method: A multidisciplinary team was assembled. NLP-based identification algorithms were developed
based on key words commonly used by physicians to describe pancreatic cysts and programmed for
automated search of electronic medical records. A pilot study was conducted prospectively in a single
institution.
Results: From March to September 2013, 566 233 reports belonging to 50 669 patients were analysed.
The mean number of patients reported with a pancreatic cyst was 88/month (range 78–98). The mean
sensitivity and specificity were 99.9% and 98.8%, respectively.
Conclusion: NLP is an effective tool to automatically identify patients with pancreatic cysts based on
electronic medical records (EMR). This highly accurate system can help capture patients ‘at-risk’ of
pancreatic cancer in a registry.
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Introduction
With an annual death rate approximating the incidence, pancre-
atic adenocarcinoma has been termed the ‘deadliest cancer’. It is
the fourth leading cause of cancer mortality in the United States
with an annual incidence of 43 920 and death rate of 37 390.1 In
spite of a marked improvement in cancer care over the past several
decades, the 5-year survival associated with pancreatic adenocar-
cinoma has changed little, rising from 3% in the 1970s to 6% in
2013.1 Pancreatic adenocarcinoma is still diagnosed in more than
80% cases at an advanced stage where available systemic therapies
remain largely ineffective.
While there is a significant pursuit of novel treatments targeted
at established pancreatic cancer, the collective research effort on
pancreatic cancer early detection and prevention (aside from
general smoking cessation and physical fitness programs) is rela-
tively small. Unlike colon, breast and prostate cancer, screening the
general population for pancreatic cancer is not feasible owing to
its low incidence (12.2/100 000/year) and the lack of effective
screening tests to identify patients at earlier stages of the disease.1,2
Pancreatic cancer screening may be applicable, however, only in
select groups of patients with a higher risk of pancreatic cancer.
This study has been presented on a Best Oral session at the 11th World
IHPBA Congress, 22–27 March 2014, Seoul.
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Patients at higher risk of pancreatic cancer include those with
pancreatic cysts and/or those with a strong family history of pan-
creatic cancer. Both of these higher risk groups represent potential
windows of opportunity for pancreatic cancer early detection and
prevention. Pancreatic cysts, especially mucinous types including
intraductal papillary mucinous neoplasms (IPMN) and mucinous
cystic neoplasms (MCN), harbour a malignancy in 20% to 90% of
patients undergoing a pancreatic resection.3,4 Hereditary or famil-
ial pancreatic cancer is estimated to be the principal aetiology in
10% of pancreatic cancers.5 The Johns Hopkins Hospital estab-
lished in 1994 the National Familial Pancreas Tumor Registry as a
research registry of families with more than one first-degree rela-
tive diagnosed with pancreatic cancer.6 However, to our knowl-
edge, no similar effort has focused on patients with pancreatic
cysts.
The incidence of pancreatic cysts ranges from 2.6% in
computed-tomography (CT) studies7 to 19.6% in magnetic reso-
nance imaging (MRI) studies8 and up to 24.3% in a Japanese
autopsy study.9 Although most pancreatic cystic lesions do not
require surgical resection, a recent review of 19 studies of mostly
surgical series from 1997 to 2011, including 1060 patients with
indeterminate pancreatic cystic lesions and final pathology found
that 41.7% of them were malignant/ aggressive.10 Considering the
high incidence of pancreatic cysts, radiologists have established
imaging recommendations to better guide their management.11
However, these recommendations do not factor in main pancre-
atic duct dilation, which may be a manifestation of main-duct
involved intraductal papillary mucinous neoplasm, a high-risk
lesion. Furthermore, the imaging recommendations are based on
cyst size (which is a less reliable criteria than previously thought)
and the ability of cross-sectional imaging studies to correctly diag-
nose the cyst (in spite of the low reported accuracy of <50% of
CT/ MRI for a specific diagnosis and the 15–20% cysts with cross-
over morphology11,12). In light of these limitations and because
pancreatic cysts are often asymptomatic and incidentally detected,
many pancreatic cystic lesions are ignored and never evaluated by
a pancreatologist (surgeon or gastroenterologist).
With an increasing adoption of electronic medical records
(EMR) systems by medical centres, more data from the patients’
charts are becoming electronic and thus available for computa-
tional processing. However, in contrast to numerical data (such as
laboratory values or blood pressure readings), data in medical
documents is narrative free text, and thus, unstructured and not
amenable to computerized applications. Natural language pro-
cessing (NLP) is the formulation and investigation of computer-
effective mechanisms for communication through natural
language.13,14 It allows computers to ‘understand’ natural language
(i.e. the language humans use to communicate) by opposition to
‘artificial’ language used by computers. NLP allows automation
and prospective tracking and is already used in hospitals for bio
surveillance and quality measures by tracking adverse events.15
The aim of this study was to automatically identify patients
with pancreatic cysts through EMR using NLP. Once feasibility is
established, the plans are to track the patients, notify their primary
care providers of their patient’s condition and provide resources
for medical decision making. The objective of this work is to
optimize the management of pancreatic cysts, and ultimately,
early detection and prevention of pancreatic cancer. In addition,
through these efforts, we seek to create a patient registry to help
improve the current knowledge of the malignant potential and
natural history of pancreatic cysts.
Methods
Population
From March 2013 to September 2013, we conducted a prospective
pilot study at a single medical centre (Wishard Memorial Hospi-
tal). Wishard Memorial Hospital is a 340-hospital bed institution
located in a major city. Longitudinal EMR of all patients who
visited this institution over the 7-month timeframe were retrieved
from the Indianapolis Network for Patient Care (INPC, 94 hospi-
tals including teaching hospitals, 110 clinics and surgery centres
and other healthcare organizations within the state of Indiana).16
Longitudinal EMR included all types of clinical, radiological, sur-
gical and pathological narrative reports. Data were analysed on
batches of monthly patients. The multidisciplinary team in charge
of this pilot study included informaticians, hospital administra-
tors, pancreatologists and pancreatic surgeons.
Data were collected and reported in strict compliance with
patient confidentiality guidelines as defined by the Indiana Uni-
versity Institutional Review Board.
Natural language processing
‘Pancreatic cyst’ concept
A list of keywords and acronyms to define the concept of a ‘pan-
creatic cyst’ was created after a literature review and United States
National Library of Medicine (National Institute of Health)
Unified Medical Language System (UMLS) review.17 Manual
analysis of clinical reports was also performed to determine com-
monly used ‘pancreatic cyst’ descriptors. The final assembled list
of ‘pancreatic cyst’ concepts was used in the NLP software for the
identification of patents with a pancreatic cyst. The extraction
process was first performed on a training set (obtained after
randomization) to confirm relevant concepts, exclude irrelevant
concepts and finally identify additional/missed concepts, thus
improving the initial keywords list. The final list of keywords used
by the query and their different patterns (‘regular expression’) and
abbreviations are presented in Table 1.
Extraction process
An Unstructured Information Management Architecture (UIMA)
framework was used for our NLP system development. UIMA is a
platform that facilitates the implementation of multiple NLP tasks
in a pipeline manner where each component’s output will be used
as the input to the next step/component.18
A rule-based algorithm was created to automatically identify
‘pancreatic cyst’ findings in the free text of electronic medical
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records. The system input was a text file containing all the reports
for all the patients. Therefore, the first step was to separate each
report using a report separator that identified the beginning and
end of a report. In the next step a Metadata annotator was built to
extract Meta information from each report such as medical record
number, report type, number, name, date and body of report. In
the next section, a sentence detector was used to identify each
sentence within the report’s body. Once the sentences were iden-
tified, the algorithm parses each sentence for at least one of the
keywords. A study on negation has shown that most clinical obser-
vations are negated in narrative clinical reports, as physicians
often record if a condition is absent or ruled out.19 We developed
a novel negation algorithm called DEEPEN (Dependency parser
negation),20 that uses dependency parser21and a set of extensive
rules built on top of it to determine whether concepts were
affirmed or negated. Dependency is a binary asymmetric relation
between a token (word or other group of characters) and its
dependents in one sentence.
The initial set of regular expressions based on the concepts
reported in Table 1 was applied to the training set. The false posi-
tives and false negative cases were analysed and required modifi-
cation. This process was repeated several times until we reached
the target precision and recall on the training set. At the final step
the algorithm was applied to the test set for evaluation.
Validation
The validation was performed manually by a group of physician
experts in pancreatology who were blinded to the results of the
NLP system. All cases were individually validated by review of
medical reports. Findings from the algorithm were compared to
the manual review, which was considered the ‘Gold Standard’. Any
discrepancy was re-evaluated by the entire team. The validation
allowed evaluation of the performance characteristics of our NLP
‘pancreatic cyst’ identification system (true positives, true nega-
tives, false negatives, false positives, sensitivity and specificity). By
pointing out the algorithm issues leading to false positives and
false negatives, the manual validation allowed improvement of the
initial computer algorithm accuracy. The algorithm was updated
every month to refine it and get closer to the gold standard, and
the evaluation provided in this study reflects the performance of
the final version of the algorithm (final version that the team
re-run at once on every monthly batch of patients during the
testing phase). No machine learning and Bayesian methodology
were used in the development of the identification algorithm.
However, DEEPEN used dependency parser which itself is a
probabilistic model that finds relations between words within a
sentence.
Statistical analysis
Data compilation was performed using Microsoft Excel 2011®
(Redmond, WA, USA). NLP programming was conducted using
Java. Descriptive statistics included numbers and percentages.
True positives were defined as patients positively identified by
both NLP algorithm and manual review. True negatives were
defined as patients with a concept negated by both NLP algorithm
and manual review. False positives were defined as patients posi-
tively identified by the NLP algorithm but not confirmed by
manual review. Conversely, false negatives were patients with a
concept negated by NLP algorithm but positively identified on
manual review.
Sensitivity and specificity were calculated using accepted defi-
nitions. The sensitivity of our identification system was defined as
the proportion of patients with ‘pancreatic cyst’ and/or ‘duct dila-
tion’ correctly identified by the NLP system compared with the
actual number of patients that manual review confirmed as con-
taining the concept of ‘pancreatic cyst’ (true positives and false
negatives). Similarly, the specificity was defined as the proportion
of patients without a ‘pancreatic cyst’ or ‘ductal dilation’ correctly
identified and excluded by our system compared with the total
number of patients that manual review confirmed as not having
the concept of a ‘pancreatic cyst’ (true negatives and false posi-
tives). The results were reported according to the Standards for
Reporting of Diagnostic Accuracy (STARD) recommendations.22
Results
Identification
There was no limitation in the type of records analysed, and both
outpatients and inpatients were included in our population. The
specific inpatient service or outpatient department/division where
patient care was provided at the time of diagnosis of a pancreatic
cyst was not one of the features extracted during the automated
Table 1 List of keywords used to define the ‘pancreatic cyst’
concept by the natural language processing software
Concept Regular expression
Pancreatic cyst (?i)(pancreatic cyst(s)? | cyst(s)?(of| in)?
the pancreas | pancreatic cystic)
Pancreatic pseudocyst (?i)(pseudo\s?cyst(s)?)
Mucinous cyst (?i)(mucinous cyst(ic | ts) neoplasm |
mucinous cystadenoma | intraductal
papillary mucinous | \b(MCN)\b |
\b(MCA)\b | \b(IPMN)|\b(IPMT)\b)
Serous cyst (?i)(serous cyst(ic | s | adenoma) |
\b(SCA)\b)
Retention cyst (?i)(retention cyst(ic | s))
Cystic neuroendocrine
tumour
(?i)(cystic neuroendocrine tumor | cystic
neuroendocrine | neuroendocrine
cyst(ic|ts)|islet cell cyst tumor|cystic islet
cell tumor)
Cystic degeneration
cancer
(?i)(cystic degeneration cancer | cystic
degeneration | degeneration cyst(ic | s))
Duct ectasia (?i)(duct(al) ectasia | ectasia of the(
pancreatic)? duct | ectasic duct)
Duct dilation (?i)(pancreatic duct(al) dila(ta)tion |
dila(ta)tion of the(pancreatic)? duct |
dilated(pancreatic)? duct)
IPMN, intraductal papillary mucinous neoplasm; IPMT, intraductal papil-
lary mucinous tumour; MCA, mucinous cystadenoma; MCN, mucinous
cystic neoplasm; SCA, serous cystadenoma.
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screening process. A total of 566 233 reports, including 50 669
unique patients, were identified during the 7-month period. Of
them, 1359 had at least one mention of a ‘pancreatic cyst’. Three of
those identified patients were further excluded (n = 1356) because
they were detected twice (one patient identified in June had pre-
viously been identified in March and two patients identified in
August and September had previously been identified in July and
August, respectively). When considering imaging studies alone, a
‘pancreatic cyst’ was originally mentioned on a CT in 84.9%,
ultrasonography in 9.5% and MRI in 5.6% of patients. The com-
puter algorithm identified 623 positive (patients with pancreatic
cyst or pancreatic ductal dilation) patients (Table 2). Manual
(physician expert) review identified 615 positive patients (nine
and one patients were found to be false positives and false nega-
tive, respectively). This resulted in a calculated prevalence of pan-
creatic cysts of 1.2%. The false positives and false negatives reports
from the final query are provided and explained in Table 3. The
most common cause of false positives was a complex sentence
structure that caused the NLP process to fail. As the negation
algorithm (DEEPEN) was not based on words location within a
sentence, but on the sentence structure and suspected relation
between words, even simple errors to the eye can have led to
system errors (false positives) (Table 3). They usually included
sentences with multiple negated findings where the algorithm did
not identify an association between the negation term and the
‘pancreatic cyst’ concept. There was only 1 false negative in 7
months and it was due to a dictation error.
System performance
Over the 7-month period, the mean sensitivity of the NLP algo-
rithm for identification of a pancreatic cyst and/or ductal dilation
was 99.85% (range 98.98–100). Similarly, the mean specificity was
98.8% (range 96.3–100) (Fig. 1). The analysis was pursued
beyond the pilot study period and the results are shown in the
dotted line on Fig. 1.
Implementation
Our system was implemented on the hospital (Wishard) server to
obtain real-time tracking. It was run daily, and the process was
executed every night. Depending on the number of daily records,
it took 2 to 3 h to complete the run. The medical record numbers
of patients identified as true positives by the algorithm were then
recorded in a database. An intermediate step of manual triage was
then required, mainly to exclude patients with a benign lesion
(pseudocyst and serous cysts). An application to alert the primary
care provider and/or the ordering physician is currently being
developed and should be installed soon. This represents the
second phase of our project. Once the alert system is imple-
mented, clinical impact and change in practice will be analysed.
Discussion
Patient care and clinical research up until the present are largely
based on retrospective or prospective collection of data into data-
bases, which is often done manually. The increased utilization of
EMR by medical centres has created new patient care and clinical
research possibilities. Through automated tracking of patient
data, EMR increases the research scope (data volume, time) and
statistical power while decreasing the required manpower utiliza-
tion. The present pilot study, over a 7-month period, demon-
strates that it is feasible and inexpensive to automate the
identification of patients with pancreatic cyst(s) and/or pancreatic
ductal dilation using natural language processing (NLP). Our
algorithm allowed tracking of those patients with high sensitivity
(99.9%) and specificity (98.8%). Although manual review
remains an important part of the study, patient capture is easier,
faster and more thorough when employing a NLP algorithm. This
has been demonstrated in previously published work from our
team.23
Current strategies for early diagnosis of pancreatic cancer have
focused on serum biomarkers. The most commonly used
biomarker is serum carbohydrate antigen 19-9 (CA19-9). Its use
as a screening tool in the general population, however, would be
suboptimal because of its low sensitivity (median 79%, range
70–90%) and specificity (median 82%, range 68–91%).24 Small
studies have suggested that the use of a combination of
biomarkers instead of an individual biomarker may improve sen-
sitivity and specificity.25 Given the high genetic heterogeneity of
pancreatic adenocarcinoma,26 such may require a large number of
biomarkers and is not likely to be routinely utilized soon. Simi-
Table 2 Monthly data results (number) for pancreatic cyst identification
Month Clinical records Patients Identified patientsa True positives True negatives False positives False negatives
March 97535 7950 227 98 128 1 0
April 78451 6419 199 93 106 0 0
May 70101 6036 186 83 102 1 0
June 78110 7514 165 79 85 1 0
July 81991 7390 196 97 97 1 1
August 79072 7534 197 86 110 1 0
September 80973 7826 186 78 104 4 0
a‘Identified patients’ represents patients with at least one mention of a pancreatic cyst or pancreatic ductal dilation in their electronic medical record.
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larly, cross-sectional imaging studies have low performance char-
acteristics for screening pancreatic cancer in the general
population.27 Beyond the identification and tracking of patients
with pancreatic cysts, our system sets ground for improved pan-
creatic cancer screening. First and foremost, our system identifies
patients with pancreatic cysts with a very high accuracy. Pancre-
atic cysts, especially mucinous cysts, are well-established precan-
cerous lesions. As they have the potential to develop into invasive
adenocarcinoma in a median of 5 years (range 2–20),3,4 tracking
them closely for clinically relevant changes may represent a
window of opportunity for pancreatic cancer prevention and early
detection. Preliminary data showed that the system could accu-
rately detect patients with premalignant cysts (mucinous cysts),
thus ensuring adequate management. However, the results were
scarce and not well refined at the time of this paper, and were not
included in the manuscript. Second, once patients with pancreatic
cysts are correctly identified, screening this ‘at risk’ subpopulation
for pancreatic cancer may be more feasible because the pretest
probability is increased, thus compensating for the suboptimal
sensitivity/specificity of currently available biomarkers/imaging
studies.
As this algorithm is adaptable, it can be incorporated into any
hospital electronic system to help capture patients with pancreatic
cysts. After this pilot study, we plan to extend the system to the
entire Indiana Network for Patient Care (INPC). The INPC con-
tains the digital medical data of >95% of Indiana’s hospital and
medical institutions as well as a large number of hospitals in other
states bordering Indiana. We anticipate the use of this programme
as a template for other regional health information organizations
(e.g. Boston, Utah, Stanford and Vanderbilt). The ultimate goal is
to move towards establishment of a national pancreatic cyst reg-
istry. This programme may lead to a more organized national
initiative for pancreatic cancer prevention and early detection,
and optimal education of both healthcare providers and patients
on current management and screening resources available.
Our study has limitations. It is a 7-month pilot study from a
single patients network (INPC) and a single institution (Wishard
Memorial Hospital). Further testing of our algorithm on other
medical centre data is required to confirm its generalizability.
Although NLP seems to be an inexpensive system, we have not
conducted a cost-effectiveness analysis. The basic engine for NLP
is 90% adaptable to a new environment. The implementation cost
in a new hospital system would be associated with time/cost for
obtaining the EMR text data, translating it into a format that our
system can read (if not already in a readable format) and creating
an alert programme compatible with the hospital system.
In spite of a high performance in identifying ‘pancreatic cysts’,
recurrent and persistent errors have been identified, especially
false-positives cases in complex structured sentences with multi-
ple negated findings. The newly developed negation algorithm
(DEEPEN) analysed sentences as a whole and was based on
relations between words instead of differential location within
one sentence. As this problem is rooted in the conception of the
Table 3 Description and explanation of the false positives (n = 9) and
false negative (n = 1) from the final query
False positives (n = 9)
Sentence in report Explanation
Specific MRCP sequences were
not included in this study
however there is concern as was
noted on prior CT scan for
pancreatic divisum however no
significant pancreatic ductal
dilation is noted.
Complex sentence
structure: multiple
negation terms in the
same sentence
There is homogenous
enhancement of the pancreas
without surrounding
inflammatory changes or
pancreatic ductal dilatation.
Complex sentence
structure: algorithm did
not identify an
association between
‘without’ and ‘pancreatic
ductal dilatation’
Linear calcific density measuring
10 x 3 mm (axial image 43) is
present within the pancreatic
body, unchanged since prior
exam, unlikely to be present
within the pancreatic duct given
no pancreatic ductal dilatation.
Complex sentence
structure: sentence
structure that causes
algorithm pre-processing
to fail.
Abdominal CT scan on 11/94
showed a large pancreas, no
abscess, pseudocyst or
phlegmon and she retained
some contrast in the gallbladder.
Complex sentence
structure: confusing
sentence formation.
There is a vague area of decreased
attenuation seen within the body
of the pancreas no evidence of
pancreatic ductal dilation or
peripancreatic inflammation.
Missing punctuation:
missing of a period after
‘pancreas’
No evidence of complicating
features or pseudocyst
formation.
Complex sentence structure
Peripancreatic inflammatory
changes with no appreciated
pancreatic mass, pseudocyst or
calcifications.
Complex sentence
structure: algorithm did
not identify an
association between ‘no’
and ‘pseudocyst’.
Transcribed by – PSC Transcription
Date – < Date> RADIOLOGY
IMPRESSION CT Abdomen and
Pelvis: Acute pancreatitis,
improved compared to prior
examination of May 2005,
without evidence of necrosis,
pseudocyst, or abscess.
Punctuation error: presence
of special characters
such as colons gives a
different structure to this
sentence
Previously seen pseudocyst in the
neck of the pancreas is no
longer appreciated.
Complex sentence
structure: algorithm
identified an association
between ‘no’ and
‘appreciated’ but not with
‘pseudocyst’
False negatives (n = 1)
Sentence in report Explanation
There is a fluid collection
near the fundus of the
stomach, without definite
wall indicates
pseudocyst.
Complex sentence structure
and dictation error: one
word missing before
‘indicates’
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negation algorithm itself and was therefore not fixable, and as only
five false positives (no impact on sensitivity) were identified by
this error, we decided to keep using this very refined algorithm.
Although ‘pseudocyst’ is a benign condition that alone does not
require screening for pancreatic cancer, we included it in the final
list of ‘pancreatic cyst’ concepts to be thorough and not miss
patients with potentially other types of cysts. Our reasoning was
based on manual review of multiple cross-sectional imaging
studies reporting a pseudocyst in spite of the absence of clinical
and radiological evidence of pancreatitis. Similarly, hypothetical
terms, such as ‘may represent’, were considered affirmed to avoid
missing patients with a potentially premalignant condition.
Incidentally discovered pancreatic cysts may be inconsequen-
tial. The data currently available on the natural history of pancre-
atic cysts and their malignant potential have some inherent
selection/referral bias, and thus the percentage of truly conse-
quential cysts might be lower in a general population screened by
an automated process. The present study is a pilot series that
aimed to confirm feasibility of an automated process using
Natural Language Processing for pancreatic cyst screening. It
accomplished this with high sensitivity and specificity. To analyse
the potential for individual lives and cost-effectiveness, further
studies including public health cost analyses would be needed to
compare the cost of a preventive strategy with follow-up exami-
nations versus the cost of pancreatic cancer treatment.
In conclusion, NLP is an effective, inexpensive and highly accu-
rate tool to automatically identify patients with pancreatic cysts.
This computerized system can help screen and track patients ‘at
risk’ of pancreatic cancer. Because of its adaptability, we believe
this system can grow in three ways. First, the system can be
expanded regionally and ultimately nationally, to build a platform
for a national pancreatic cyst registry, one arm of a pancreatic
cancer early detection initiative. Second, the NLP algorithm used
in the present study can be adapted to identify patients at risk of
pancreatic cancer as a result of inherited conditions, e.g. a family
history of pancreatic cancer. This is already underway with plans
to pilot this study at a central Indiana hospital. Finally, the NLP
algorithm used in the present study can be modified and applied
to identify patients with other (i.e. non-pancreatic) precancerous
lesions or conditions.
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